Lexicon Pharmaceuticals (LXRX) Current Deferred Revenue (2010 - 2025)

Lexicon Pharmaceuticals' (LXRX) quarterly Current Deferred Revenue came in at $4.3 million in Q3 2025, down 75.35% on a QoQ basis from $17.5 million in Q2 2025.

Lexicon Pharmaceuticals (LXRX) Current Deferred Revenue (2010 - 2025) Analysis & Trends

Lexicon Pharmaceuticals (LXRX) has 11 years of Current Deferred Revenue data on file, last reported at $4.3 million in Q3 2025.

  • On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $4.3 million in Q3 2025; TTM through Sep 2025 was $4.3 million, a N/A change from a year earlier, with the FY2018 full-year figure at $2.3 million, down 94.2% from the prior year.
  • Current Deferred Revenue for Q3 2025 stood at $4.3 million, down from $17.5 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for LXRX reached as high as $45.0 million in Q1 2025 and fell as low as $4.3 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Lexicon Pharmaceuticals 979.13 Mn 808.47 Mn 20.99 Mn

Historic Data

Download Data
DateValue
Sep 30, 2025 4.30 Mn
Jun 30, 2025 17.46 Mn
Mar 31, 2025 45.00 Mn
Sep 30, 2019 1.12 Mn
Jun 30, 2019 2.24 Mn
Mar 31, 2019 2.43 Mn
Dec 31, 2018 2.34 Mn
Sep 30, 2018 2.12 Mn
Jun 30, 2018 5.12 Mn
Mar 31, 2018 7.44 Mn
Dec 31, 2017 40.35 Mn
Sep 30, 2017 48.74 Mn
Jun 30, 2017 63.20 Mn
Mar 31, 2017 69.17 Mn
Dec 31, 2016 63.37 Mn
Sep 30, 2016 78.87 Mn
Jun 30, 2016 61.53 Mn
Mar 31, 2016 70.76 Mn
Dec 31, 2015 76.50 Mn
Sep 30, 2015 1.74 Mn